Letermovir (CMV prophylaxis after stem cell transplantation, < 18 years); Benefit assessment according to §35a SGB V

Read full text Summarise with VIRAT
Authors: Institute for Quality and Efficiency in Health Care
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Fields of Study & Subjects

Cytomegalovirus and herpesvirus research Viral-associated cancers and disorders Herpesvirus Infections and Treatments

Publication details

Journal / source
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Publication date
20 March 2026
Language
EN